CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) — Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1/1b clinical trial evaluating its lead program, CryptiVax-1001, targeting advanced high-grade serous ovarian ...
Subscribe to BIOTECanada’s news feed.
Click on “Follow” and decide if you want to get news from BIOTECanada via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to BIOTECanada comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from BIOTECanada which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: Home - BIOTECanada